Recent advances in systemic therapy for hepatocellular carcinoma

Area of Science:

• Hepatology
• Medical Oncology
• Cancer Research

Background:

• Hepatocellular carcinoma (HCC) is a globally prevalent and deadly malignancy.
• Treatment options for advanced HCC remain limited, with conventional chemotherapy often proving ineffective.
• Sorafenib was the sole systemic therapy for advanced HCC for over a decade.

Purpose of the Study:

• To review the advancements in molecular targeted agents for HCC.
• To summarize the progress of immunotherapies in HCC treatment.
• To highlight the emerging combination of targeted therapy and immunotherapy.

Main Methods:

• Literature review of molecular targeted therapies in HCC.
• Analysis of clinical trial data for immunotherapies in HCC.
• Synthesis of recent research on combined treatment strategies.

Main Results:

• Molecular targeted therapies have significantly altered the treatment landscape for advanced HCC.
• Immune checkpoint inhibitors are increasingly integrated into HCC treatment protocols.
• Combinations of targeted therapy and immunotherapy show promise for enhanced immune response.

Conclusions:

• The therapeutic landscape for advanced HCC has been transformed by recent advancements.
• Targeted therapies and immunotherapies represent the forefront of HCC treatment innovation.
• Future strategies likely involve synergistic combinations of these novel agents.